文献速递中医内科中药与中成药合理使用

黄芪汤调控lnc-C18orf26-1/miR-663a/TGF-β轴抑制肝星状细胞

Huangqi Decoction, a compound Chinese herbal medicine, inhibits the proliferation and activation of hepatic stellate cells by regulating the long noncoding RNA-C18orf26-1/microRNA-663a/transforming growth factor-β axis.
PubMed 文献 · J Integr Med · 2022-11-16

本研究探讨黄芪汤抑制肝纤维化的分子机制。实验发现lnc-C18orf26-1在TGF-β1激活的肝星状细胞中上调并竞争性结合miR-663a;黄芪汤可升高miR-663a、降低lnc-C18orf26-1,从而抑制肝星状细胞增殖活化及TGF-β1/TGF-βRI/p-Smad2通路。

要点

  • 黄芪汤抑制肝星状细胞增殖与活化,部分通过调控lnc-C18orf26-1/miR-663a轴实现。
  • lnc-C18orf26-1竞争性结合miR-663a,敲低该lncRNA可抑制TGF-β1/Smad通路。
  • 黄芪汤下调COL1A2、α-SMA、TGF-β1、TGF-βRI及p-Smad2,该效应可被miR-663a抑制剂逆转。

核心结论

  • lnc-C18orf26-1和miR-663a是肝纤维化的潜在治疗靶点。
  • 黄芪汤至少部分通过调控lnc-C18orf26-1/miR-663a/TGF-β1/TGF-βRI/p-Smad2轴抑制肝星状细胞增殖和活化。

研究设计与样本

  • 体外细胞实验:采用肝星状细胞,转染miR-663a mimic/inhibitor及lnc-C18orf26-1 siRNA。
  • 采用qRT-PCR检测lnc-C18orf26-1、miR-663a及相关基因表达。
  • 采用WST-1法评估肝星状细胞增殖率,Western blotting检测COL1A2、α-SMA及TGF-β/Smad通路相关蛋白。
  • 采用微阵列分析鉴定miR-663a调控的lncRNA,RNA hybrid预测结合位点,荧光素酶报告基因实验验证相互作用。

主要发现

  • lnc-C18orf26-1在TGF-β1激活的肝星状细胞中表达上调,并竞争性结合miR-663a。
  • 敲低lnc-C18orf26-1可抑制肝星状细胞增殖和活化,下调TGF-β1刺激的α-SMA和COL1A2表达,并抑制TGF-β1/Smad信号通路。
  • 黄芪汤抑制肝星状细胞增殖和活化,升高miR-663a表达并降低lnc-C18orf26-1表达。
  • 黄芪汤抑制肝星状细胞中COL1A2、α-SMA、TGF-β1、TGF-βRI和p-Smad2表达,这些效应可被miR-663a抑制剂逆转。

临床怎么用

  • 黄芪汤抗肝纤维化作用与调控lnc-C18orf26-1/miR-663a/TGF-β1/TGF-βRI/p-Smad2轴相关,为临床用于肝纤维化提供分子依据。
  • lnc-C18orf26-1和miR-663a可作为肝纤维化潜在治疗靶点,但尚需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Huangqi Decoction (HQD), a classical traditional Chinese medicine formula, has been used as a valid treatment for alleviating liver fibrosis; however, the underlying molecular mechanism is still unknown. Although our previous studies showed that microRNA-663a (miR-663a) suppresses the proliferation and activation of hepatic stellate cells (HSCs) and the transforming growth factor-β/small mothers against decapentaplegic (TGF-β/Smad) pathway, whether long noncoding RNAs (lncRNAs) are involved in HSC activation via the miR-663a/TGF-β/Smad signaling pathway has not yet reported. The present study aimed to investigate the roles of lncRNA lnc-C18orf26-1 in the activation of HSCs and the mechanism by which HQD inhibits hepatic fibrosis. METHODS: The expression levels of lnc-C18orf26-1, miR-663a and related genes were measured by quantitative reverse transcription-polymerase chain reaction. HSCs were transfected with the miR-663a mimic or inhibitor and lnc-C18orf26-1 small interfering RNAs. The water-soluble tetrazolium salt-1 assay was used to assess the proliferation rate of HSCs. Changes in lncRNA expression were evaluated in miR-663a-overexpressing HSCs by using microarray to identify miR-663a-regulated lncRNAs. RNA hybrid was used to predict the potential miR-663a binding sites on lncRNAs. Luciferase reporter assays further confirmed the interaction between miR-663a and the lncRNA. The expression levels of collagen α-2(I) chain (COL1A2), α-smooth muscle actin (α-SMA) and TGF-β/Smad signaling pathway-related proteins were determined using Western blotting. RESULTS: Lnc-C18orf26-1 was upregulated in TGF-β1-activated HSCs and competitively bound to miR-663a. Knockdown of lnc-C18orf26-1 inhibited HSC proliferation and activation, downregulated TGF-β1-stimulated α-SMA and COL1A2 expression, and inhibited the TGF-β1/Smad signaling pathway. HQD suppressed the proliferation and activation of HSCs. HQD increased miR-663a expression and decreased lnc-C18orf26-1 expression in HSCs. Further studies showed that HQD inhibited the expression of COL1A2, α-SMA, TGF-β1, TGF-β type I receptor (TGF-βRI) and phosphorylated Smad2 (p-Smad2) in HSCs, and these effects were reversed by miR-663a inhibitor treatment. CONCLUSION: Our study identified lnc-C18orf26-1 and miR-663a as promising therapeutic targets for hepatic fibrosis. HQD inhibits HSC proliferation and activation at least partially by regulating the lnc-C18orf26-1/miR-663a/TGF-β1/TGF-βRI/p-Smad2 axis.

来源:J Integr Med,查看原文。版权归原作者所有。

引用

  1. Dong BS, Liu FQ, Yang WN, et al. Huangqi Decoction, a compound Chinese herbal medicine, inhibits the proliferation and activation of hepatic stellate cells by regulating the long noncoding RNA-C18orf26-1/microRNA-663a/transforming growth factor-β axis. J Integr Med. 2022. PMID: 36456413. doi:10.1016/j.joim.2022.11.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。